Literature DB >> 5925319

Antigenicity of the M proteins of group A hemolytic streptococci. 3. Antibody responses and cutaneous hypersensitivity in humans.

E N Fox, M K Wittner, A Dorfman.   

Abstract

Highly purified M proteins were used for determining cutaneous hypersensitivity and type-specific circulating antibodies in normal adults and infants. 80% of 91 adults and 8% of 59 infants exhibited a transient delayed cutaneous reaction to at least two of types 12, 14, and 24 M proteins. Antibodies assayed by passive hemagglutination were observed in 90% of the adults and 13% of the infants. Vaccines of 10 microg of alum-precipitated M protein or 20 microg of the soluble antigen were administered to adults not exhibiting delayed hypersensitivity. Within 2 wk hemagglutination liters increased significantly in 31 of 33 subjects. Preimmunization antibody levels indicated that these responses were probably anamnestic reactions from previous exposures to homologous serotypes of group A streptococci. Sera exhibiting large increments in antibody titers resulting from M protein inoculations also had type-specific bactericidal properties. "Attenuated" M proteins, produced by partial degradation with trypsin induced only minimal cutaneous reactions in hypersensitive adults, but still retained most of the antigenic specificity when assayed in vitro and in vivo. The utility of M protein vaccines for human use is discussed in reference to the low incidence of cutaneous hypersensitivity in infants, the potentials of polyvalent attenuated M protein vaccines and the apparent absence of immune cross-reactivity between pure M proteins and human heart and kidney tissues.

Entities:  

Mesh:

Substances:

Year:  1966        PMID: 5925319      PMCID: PMC2138333          DOI: 10.1084/jem.124.6.1135

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  16 in total

1.  STREPTOCOCCAL RELATED GLOMERULONEPHRITIS. I. ISOLATION, IMMUNOCHEMISTRY AND COMPARATIVE CHEMISTRY OF SOLUBLE FRACTIONS FROM TYPE 12 NEPHRITOGENIC STREPTOCOCCI AND HUMAN GLOMERULI.

Authors:  A S MARKOWITZ; C F LANGE
Journal:  J Immunol       Date:  1964-04       Impact factor: 5.422

2.  ANTIGENICITY OF THE M PROTEINS OF GROUP A HEMOLYTIC STREPTOCOCCI.

Authors:  E N FOX
Journal:  J Immunol       Date:  1964-11       Impact factor: 5.422

3.  An immunological cross-reaction between group-A streptococcal cells and human heart tissue.

Authors:  M H KAPLAN; M MEYESERIAN
Journal:  Lancet       Date:  1962-04-07       Impact factor: 79.321

4.  Type-specific antibody formation in man following injection of streptococcal M protein.

Authors:  W C SCHMIDT
Journal:  J Infect Dis       Date:  1960 May-Jun       Impact factor: 5.226

5.  Recall of type specific antibodies in man by injections of streptococcal cell walls.

Authors:  E V POTTER; G H STOLLERMAN; A C SIEGEL
Journal:  J Clin Invest       Date:  1962-02       Impact factor: 14.808

6.  The cellular transfer in humans of delayed cutaneous reactivity to hemolytic streptococci.

Authors:  H S LAWRENCE
Journal:  J Immunol       Date:  1952-02       Impact factor: 5.422

7.  The delayed hypersensitivity induced by antigen-antibody complexes.

Authors:  S RAFFEL; J M NEWEL
Journal:  J Exp Med       Date:  1958-12-01       Impact factor: 14.307

8.  IMMUNOLOGIC RELATION OF STREPTOCOCCAL AND TISSUE ANTIGENS. II. CROSS-REACTION OF ANTISERA TO MAMMALIAN HEART TISSUE WITH A CELL WALL CONSTITUENT OF CERTAIN STRAINS OF GROUP A STREPTOCOCCI.

Authors:  M H KAPLAN; M L SUCHY
Journal:  J Exp Med       Date:  1964-04-01       Impact factor: 14.307

9.  Accessory plasma factors involved in the bactericidal test for type-specific antibody to group A streptococci. I. A typical behavior of some human and rabbit bloods.

Authors:  G H STOLLERMAN; F S KANTOR; B D GORDON
Journal:  J Exp Med       Date:  1958-10-01       Impact factor: 14.307

10.  Differentiation of group A streptococci with a common R antigen into three serological types, with special reference to the bactericidal test.

Authors:  R C LANCEFIELD
Journal:  J Exp Med       Date:  1957-10-01       Impact factor: 14.307

View more
  23 in total

1.  Vaccination against rheumatic heart disease: a review of current research strategies and challenges.

Authors:  Manisha Pandey; Michael R Batzloff; Michael F Good
Journal:  Curr Infect Dis Rep       Date:  2012-08       Impact factor: 3.725

Review 2.  Advances in potential M-protein peptide-based vaccines for preventing rheumatic fever and rheumatic heart disease.

Authors:  Michael R Batzloff; Manisha Pandey; Colleen Olive; Michael F Good
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

Review 3.  M proteins of group A streptococci.

Authors:  E N Fox
Journal:  Bacteriol Rev       Date:  1974-03

4.  Secondary and apparent primary antibody responses after group A streptococcal vaccination of 21 children.

Authors:  B F Massell; J G Michael; J Amezcua; M Siner
Journal:  Appl Microbiol       Date:  1968-03

5.  Quantitative aspects of the M protein capillary precipitin test.

Authors:  J O Cohen; L Pine
Journal:  Appl Microbiol       Date:  1968-01

6.  Impaired lymphocyte stimulation by some streptococcal antigens in patients with recurrent aphthous stomatitis and rheumatic heart disease.

Authors:  T C Francis; J J Oppenheim
Journal:  Clin Exp Immunol       Date:  1970-04       Impact factor: 4.330

7.  [Recent progress in the fight against acute arthritic rheumatism and future perspectives: WHO Memorandum].

Authors: 
Journal:  Bull World Health Organ       Date:  1979       Impact factor: 9.408

8.  Homologous and heterologous protection of mice with group A streptococcal M protein vaccines.

Authors:  M K Wittner; E N Fox
Journal:  Infect Immun       Date:  1977-01       Impact factor: 3.441

9.  Protective study with a group A streptococcal M protein vaccine. Infectivity challenge of human volunteers.

Authors:  E N Fox; R H Waldman; M K Wittner; A A Mauceri; A Dorfman
Journal:  J Clin Invest       Date:  1973-08       Impact factor: 14.808

10.  Induction of human gamma interferon by structurally defined polypeptide fragments of group A streptococcal M protein.

Authors:  D A Weigent; E H Beachey; T Huff; J W Peterson; G J Stanton; S Baron
Journal:  Infect Immun       Date:  1984-01       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.